SRC and neoplasm: In this study, we specifically examined the effects of targeting the FAK-Src complex in pediatric and AYA sarcomas by examining pFAK and pSrc expressions in clinically derived tumor material of DSRCT, ES, ARMS, and ERMS patients and by examining in vitro and in vivo effects of the FAK inhibitor defactinib and the Abl/SFK inhibitor dasatinib combination treatment.